Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This research study is studying a targeted therapy as a possible treatment for relapsed or
refractory Waldenstrom's Macroglobulinemia (WM). This study is using the study intervention
ABT-199.